Sophia Ktori, GEN News Highlights, 08 August 2017, http://www.genengnews.com/gen-news-highlights/crispr-screen-identifies-top-100-essential-genes-for-cancer-immunotherapy/81254771
One of CRISPR’s most promising therapeutic uses is in the creation of cancer immunotherapies. Scientists at the National Institute of Health, working in close collaboration with Feng Zhang of the Broad Institute, developed a CRISPR/Cas9 screen allowing them to test many genes for their effect on T-cell responses. The results, published in Nature (http://www.nature.com/nature/journal/vaop/ncurrent/full/nature23477.html), identified 100 genes that, upon mutating, impacted resistance to T-cell attack. This report provides a potential explanation as to why some patients do not demonstrate positive response to immunotherapy treatments and underscores the potential benefits of individualized medicine.
David Cyranoski, Nature News, 03 August 2017 http://www.nature.com/news/authors-retract-controversial-ngago-gene-editing-study-1.22412
The authors of the highly controversial NgAgo gene editing paper published in Nature Biotechnology in May 2016 have issued a retraction. The original article demonstrated that NgAgo was an Argonaut-based DNG-guided endonuclease that could be used to knock out or replace genes more accurately and with greater versatility than CRISPR/Cas. After publication, many researchers tried to replicate the results with little success. The authors retracted the study citing scientists’ inability to replicate the main finding.
Ashley Yeager, The Scientist, 31 July 2017, http://www.the-scientist.com/?articles.view/articleNo/49994/title/Human-Genetic-Variation-May-Complicate-CRISPR/
CRISPR has been heralded as a potential treatment for many chronic genetic disorders, however implementing them in the human genome could be harder than first expected. In a recent Nature Medicine article published by David Scott and Feng Zhang (http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4377.html), guide RNAs for 12 genes related to various diseases were compared to whole genome sequencing data from the Exome Aggregation Consortium and the 1,000 Genomes database. Scott and Zhang found that the number of off-target sites computationally predicted for guides ranged from 0 to over 10,000 depending on the subject’s individual genetic variation. This study indicates that genetic screening may be required before CRISPR therapies to ensure that off-target effects are limited.
Pam Belluck, 2 August 2017, New York Times https://www.nytimes.com/2017/08/02/science/gene-editing-human-embryos.html
In a newly published Nature article (https://www.nature.com/nature/journal/vaop/ncurrent/full/nature23305.html), a multinational group of researchers from the United States, South Korea, and China successfully corrected the autosomal dominant mutation HCM, responsible for myocardial disease. In contrast to previous attempts, this study co-injected the CRISPR/Cas machinery with the sperm which resulted in non-mosaic embryos that could be safely implanted. Further demonstrating the advances made in this study, full genome sequencing revealed no off-target edits. While this report demonstrates the potential genome editing has to eliminate genetic disease, more research is required to ensure efficacy along with public discussions over the ethical implications.
Diana Kwon, The Scientist, 17 July 2017, http://www.the-scientist.com/?articles.view/articleNo/49910/title/CRISPR-Restores-Muscle-Function-in-Mice/
A new study published in Nature Medicine (https://www.ncbi.nlm.nih.gov/pubmed/28714989) has demonstrated the potential for CRISPR to restore muscle function in congenital muscular dystrophy type 1A. Researchers used CRISPR gene editing to cut the DNA in two places, allowing the aberrant region to be removed during DNA repair – effectively creating a normal splice.
Jackson, R.N. et. al. (2017) Current Opinions in Microbiology. 37:110-119. https://www.ncbi.nlm.nih.gov/pubmed/28646675
The CRISPR adaptive immune systems in bacteria and archaea are regulated through a series of checkpoints that prevent the self-targeting of the hosts genetic material. Understanding the mechanisms of CRISPR regulation may allow for fewer off-target effects during CRISPR gene editing. This review covers our current understanding of CRISPR regulation and identifies conserved themes.
Sontheimer E.J and Davidson, A.R. (2017) Current Opinions in Microbiology. 37:120-127. https://www.ncbi.nlm.nih.gov/pubmed/28668720
As with every immune system, invading organisms have developed ways to bypass an organism’s defenses. The CRISPR/Cas system is no different with viruses developing anti-CRISPR proteins. This review surveys anti-CRISPR proteins and how they could be used to enhance CRISPR gene editing.
Luttgeharm, K.D. et. al, (2017) Biotechniques, 62:268-274. https://www.ncbi.nlm.nih.gov/pubmed/28625156
Detection of CRISPR mutations and the determination of mutation zygosity often slows gene editing workflows to a crawl. In this Biotechniques report, Luttgeharm et. al. describe an optimized T7 Endonuclease I heteroduplex cleavage assay that detects a wide variety of mutations and predicts mutation zygosity for individual diploid cell lines and organisms.
Karvelis, T. et. a. (2017) Current Opinions in Microbiology 37:88-94. https://www.ncbi.nlm.nih.gov/pubmed/28645099
While the CRISPR/Cas9 system is a significant improvement over previous gene editing technology, limitations remain. A significant constraint is the requirement for the PAM sequence. By identifying Cas9 variants from additional species and in vitro evolution of identified variants, scientists will be able to diversify the number of sequences targeted.
Khin, C, N., et. al. (2017) PLOSOne, 12(6):e0178768. https://www.ncbi.nlm.nih.gov/pubmed/28609472
A new study in PLOSOne has found no evidence of gene editing activity with Natronobacterium gregoryi Argonaute (NgAgo). Previously NgAgo had been described as a DNA targeting, DNA guided endonuclease similar to the CRISPR/Cas system. However, since its first report few labs have been able to duplicate the results. In this report researchers injected over 100 mouse zygotes with the NgAgo plasmid supplied by AddGene and found no evidence of successful gene editing.